We tracked 32 orthopedic funding announcements in 2022, a modest slowdown after the flurry of investor activity in the wake of the pandemic. Our chart of the month shows the number of orthopedic funding announcements we’ve covered by segment from 2016 to 2022.
Sustained economic pressure brought an end to the post-pandemic boom of the medtech capital markets. Unprecedented company valuations have settled, startups no longer have viable dual-track options to leverage in acquisition talks and investors have shifted away from growth-at-all-costs to companies with a reasonable chance at profitability.
Of the nearly 250 announcements we’ve tracked since 2016, spine remains the most active segment with 28% of the total. Spine saw even more activity than usual in 2022, accounting for more than a third of all announcements. Orthobiologics rebounded after a few slow years leading into the pandemic, and trauma has dipped after a flurry of foot and ankle activity in 2020 and 2021.
Enabling technology is the fastest-growing funding category. It accounted for just 7% of funding announcements in 2016 but more than 28% in 2022. Since 2019, enabling technology has accounted for a minimum of 20% of all funding announcements.
We tracked 32 orthopedic funding announcements in 2022, a modest slowdown after the flurry of investor activity in the wake of the pandemic. Our chart of the month shows the number of orthopedic funding announcements we’ve covered by segment from 2016 to 2022.
Sustained economic pressure brought an end to the post-pandemic boom of the medtech...
We tracked 32 orthopedic funding announcements in 2022, a modest slowdown after the flurry of investor activity in the wake of the pandemic. Our chart of the month shows the number of orthopedic funding announcements we’ve covered by segment from 2016 to 2022.
Sustained economic pressure brought an end to the post-pandemic boom of the medtech capital markets. Unprecedented company valuations have settled, startups no longer have viable dual-track options to leverage in acquisition talks and investors have shifted away from growth-at-all-costs to companies with a reasonable chance at profitability.
Of the nearly 250 announcements we’ve tracked since 2016, spine remains the most active segment with 28% of the total. Spine saw even more activity than usual in 2022, accounting for more than a third of all announcements. Orthobiologics rebounded after a few slow years leading into the pandemic, and trauma has dipped after a flurry of foot and ankle activity in 2020 and 2021.
Enabling technology is the fastest-growing funding category. It accounted for just 7% of funding announcements in 2016 but more than 28% in 2022. Since 2019, enabling technology has accounted for a minimum of 20% of all funding announcements.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
